http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 21 Jul 2026 08:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Vaxart+to+Participate+in+BTIG+Biotechnology+Conference+2026/26792513.html <p align="left">SOUTH SAN FRANCISCO, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that members of its management team will participate in the BTIG Virtual Biotechnology Conference taking place virtually July 28, 2026.</p> <p><strong>BTIG Biotechnology Conference 2026</strong><br/>Date: Tuesday, July 28, 2026<br/>Format: 1x1 Meetings<br/>Location: Virtual<br/><br/>Institutional Investors interested in meeting with Vaxart management should contact their BTIG representative.</p> <p><strong>About Vaxart</strong><br/>Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines http://www.streetinsider.com/Press+Releases/Vaxart+to+Participate+in+BTIG+Biotechnology+Conference+2026/26792513.html Tue, 21 Jul 2026 08:00:00 -0400 O.20329759 VXRT http://www.streetinsider.com/Press+Releases/Vaxart+to+Participate+in+BTIG+Biotechnology+Conference+2026/26792513.html <p align="left">SOUTH SAN FRANCISCO, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that members of its management team will participate in the BTIG Virtual Biotechnology Conference taking place virtually July 28, 2026.</p> <p><strong>BTIG Biotechnology Conference 2026</strong><br/>Date: Tuesday, July 28, 2026<br/>Format: 1x1 Meetings<br/>Location: Virtual<br/><br/>Institutional Investors interested in meeting with Vaxart management should contact their BTIG representative.</p> <p><strong>About Vaxart</strong><br/>Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines http://www.streetinsider.com/Press+Releases/Vaxart+to+Participate+in+BTIG+Biotechnology+Conference+2026/26792513.html Tue, 21 Jul 2026 08:00:00 -0400 O.20329759 VXRT http://www.streetinsider.com/Globe+Newswire/Vaxart+to+Participate+in+BTIG+Biotechnology+Conference+2026/26792513.html <p align="left">SOUTH SAN FRANCISCO, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that members of its management team will participate in the BTIG Virtual Biotechnology Conference taking place virtually July 28, 2026.</p> <p><strong>BTIG Biotechnology Conference 2026</strong><br/>Date: Tuesday, July 28, 2026<br/>Format: 1x1 Meetings<br/>Location: Virtual<br/><br/>Institutional Investors interested in meeting with Vaxart management should contact their BTIG representative.</p> <p><strong>About Vaxart</strong><br/>Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines http://www.streetinsider.com/Globe+Newswire/Vaxart+to+Participate+in+BTIG+Biotechnology+Conference+2026/26792513.html Tue, 21 Jul 2026 08:00:00 -0400 O.20329759 VXRT http://www.streetinsider.com/Globe+Newswire/Vaxart+to+Participate+in+BTIG+Biotechnology+Conference+2026/26792513.html <p align="left">SOUTH SAN FRANCISCO, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that members of its management team will participate in the BTIG Virtual Biotechnology Conference taking place virtually July 28, 2026.</p> <p><strong>BTIG Biotechnology Conference 2026</strong><br/>Date: Tuesday, July 28, 2026<br/>Format: 1x1 Meetings<br/>Location: Virtual<br/><br/>Institutional Investors interested in meeting with Vaxart management should contact their BTIG representative.</p> <p><strong>About Vaxart</strong><br/>Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines http://www.streetinsider.com/Globe+Newswire/Vaxart+to+Participate+in+BTIG+Biotechnology+Conference+2026/26792513.html Tue, 21 Jul 2026 08:00:00 -0400 O.20329759 VXRT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+16++Filed+by%3A+Finney+Kevin/26789673.html si-local-file:///var/storage/secattach/20260720/26789673.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+16++Filed+by%3A+Finney+Kevin/26789673.html Mon, 20 Jul 2026 16:04:00 -0400 O.20329759 VXRT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+16++Filed+by%3A+Finney+Kevin/26789673.html si-local-file:///var/storage/secattach/20260720/26789673.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+16++Filed+by%3A+Finney+Kevin/26789673.html Mon, 20 Jul 2026 16:04:00 -0400 O.20329759 VXRT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+16++Filed+by%3A+BREITMEYER+JAMES+B/26785542.html si-local-file:///var/storage/secattach/20260717/26785542.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+16++Filed+by%3A+BREITMEYER+JAMES+B/26785542.html Fri, 17 Jul 2026 21:51:00 -0400 O.20329759 VXRT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+16++Filed+by%3A+BREITMEYER+JAMES+B/26785542.html si-local-file:///var/storage/secattach/20260717/26785542.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+16++Filed+by%3A+BREITMEYER+JAMES+B/26785542.html Fri, 17 Jul 2026 21:51:00 -0400 O.20329759 VXRT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+16++Filed+by%3A+Wheadon+David+E./26785539.html si-local-file:///var/storage/secattach/20260717/26785539.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+16++Filed+by%3A+Wheadon+David+E./26785539.html Fri, 17 Jul 2026 21:50:00 -0400 O.20329759 VXRT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+16++Filed+by%3A+Wheadon+David+E./26785539.html si-local-file:///var/storage/secattach/20260717/26785539.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+16++Filed+by%3A+Wheadon+David+E./26785539.html Fri, 17 Jul 2026 21:50:00 -0400 O.20329759 VXRT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+16++Filed+by%3A+Watson+W.+Mark/26785540.html si-local-file:///var/storage/secattach/20260717/26785540.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+16++Filed+by%3A+Watson+W.+Mark/26785540.html Fri, 17 Jul 2026 21:50:00 -0400 O.20329759 VXRT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+16++Filed+by%3A+Watson+W.+Mark/26785540.html si-local-file:///var/storage/secattach/20260717/26785540.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+16++Filed+by%3A+Watson+W.+Mark/26785540.html Fri, 17 Jul 2026 21:50:00 -0400 O.20329759 VXRT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+16++Filed+by%3A+HERON+ELAINE+J/26785541.html si-local-file:///var/storage/secattach/20260717/26785541.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+16++Filed+by%3A+HERON+ELAINE+J/26785541.html Fri, 17 Jul 2026 21:50:00 -0400 O.20329759 VXRT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+16++Filed+by%3A+HERON+ELAINE+J/26785541.html si-local-file:///var/storage/secattach/20260717/26785541.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+16++Filed+by%3A+HERON+ELAINE+J/26785541.html Fri, 17 Jul 2026 21:50:00 -0400 O.20329759 VXRT http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+16/26784438.html si-local-file:///var/storage/secattach/20260717/26784438.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+16/26784438.html Fri, 17 Jul 2026 16:10:00 -0400 O.20329759 VXRT http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+16/26784438.html si-local-file:///var/storage/secattach/20260717/26784438.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+16/26784438.html Fri, 17 Jul 2026 16:10:00 -0400 O.20329759 VXRT http://www.streetinsider.com/Press+Releases/Vaxart+Announces+Results+of+Annual+Meeting+of+Stockholders/26784328.html <p align="justify">SOUTH SAN FRANCISCO, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, yesterday held its Annual Meeting of Stockholders (the “Annual Meeting”) in a virtual-only format. Results from the Annual Meeting indicate that two proposals were approved and one proposal was rejected by Vaxart stockholders.</p> <p align="justify">Stockholders voted in favor of the following proposals in alignment with the Board of Directors’ recommendations:</p> <ul type="disc"><li style="text-align:justify;">Election of six director nominees to serve http://www.streetinsider.com/Press+Releases/Vaxart+Announces+Results+of+Annual+Meeting+of+Stockholders/26784328.html Fri, 17 Jul 2026 16:05:00 -0400 A.23795053 O.20329759 O.30693091 VXRT http://www.streetinsider.com/Press+Releases/Vaxart+Announces+Results+of+Annual+Meeting+of+Stockholders/26784328.html <p align="justify">SOUTH SAN FRANCISCO, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, yesterday held its Annual Meeting of Stockholders (the “Annual Meeting”) in a virtual-only format. Results from the Annual Meeting indicate that two proposals were approved and one proposal was rejected by Vaxart stockholders.</p> <p align="justify">Stockholders voted in favor of the following proposals in alignment with the Board of Directors’ recommendations:</p> <ul type="disc"><li style="text-align:justify;">Election of six director nominees to serve http://www.streetinsider.com/Press+Releases/Vaxart+Announces+Results+of+Annual+Meeting+of+Stockholders/26784328.html Fri, 17 Jul 2026 16:05:00 -0400 A.23795053 O.20329759 O.30693091 VXRT http://www.streetinsider.com/Press+Releases/Vaxart+Announces+Results+of+Annual+Meeting+of+Stockholders/26784328.html <p align="justify">SOUTH SAN FRANCISCO, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, yesterday held its Annual Meeting of Stockholders (the “Annual Meeting”) in a virtual-only format. Results from the Annual Meeting indicate that two proposals were approved and one proposal was rejected by Vaxart stockholders.</p> <p align="justify">Stockholders voted in favor of the following proposals in alignment with the Board of Directors’ recommendations:</p> <ul type="disc"><li style="text-align:justify;">Election of six director nominees to serve http://www.streetinsider.com/Press+Releases/Vaxart+Announces+Results+of+Annual+Meeting+of+Stockholders/26784328.html Fri, 17 Jul 2026 16:05:00 -0400 A.23795053 O.20329759 O.30693091 VXRT http://www.streetinsider.com/Press+Releases/Vaxart+Announces+Results+of+Annual+Meeting+of+Stockholders/26784328.html <p align="justify">SOUTH SAN FRANCISCO, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, yesterday held its Annual Meeting of Stockholders (the “Annual Meeting”) in a virtual-only format. Results from the Annual Meeting indicate that two proposals were approved and one proposal was rejected by Vaxart stockholders.</p> <p align="justify">Stockholders voted in favor of the following proposals in alignment with the Board of Directors’ recommendations:</p> <ul type="disc"><li style="text-align:justify;">Election of six director nominees to serve http://www.streetinsider.com/Press+Releases/Vaxart+Announces+Results+of+Annual+Meeting+of+Stockholders/26784328.html Fri, 17 Jul 2026 16:05:00 -0400 A.23795053 O.20329759 O.30693091 VXRT http://www.streetinsider.com/Globe+Newswire/Vaxart+Announces+Results+of+Annual+Meeting+of+Stockholders/26784328.html <p align="justify">SOUTH SAN FRANCISCO, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, yesterday held its Annual Meeting of Stockholders (the “Annual Meeting”) in a virtual-only format. Results from the Annual Meeting indicate that two proposals were approved and one proposal was rejected by Vaxart stockholders.</p> <p align="justify">Stockholders voted in favor of the following proposals in alignment with the Board of Directors’ recommendations:</p> <ul type="disc"><li style="text-align:justify;">Election of six director nominees to serve http://www.streetinsider.com/Globe+Newswire/Vaxart+Announces+Results+of+Annual+Meeting+of+Stockholders/26784328.html Fri, 17 Jul 2026 16:05:00 -0400 A.23795053 O.20329759 O.30693091 VXRT http://www.streetinsider.com/Globe+Newswire/Vaxart+Announces+Results+of+Annual+Meeting+of+Stockholders/26784328.html <p align="justify">SOUTH SAN FRANCISCO, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, yesterday held its Annual Meeting of Stockholders (the “Annual Meeting”) in a virtual-only format. Results from the Annual Meeting indicate that two proposals were approved and one proposal was rejected by Vaxart stockholders.</p> <p align="justify">Stockholders voted in favor of the following proposals in alignment with the Board of Directors’ recommendations:</p> <ul type="disc"><li style="text-align:justify;">Election of six director nominees to serve http://www.streetinsider.com/Globe+Newswire/Vaxart+Announces+Results+of+Annual+Meeting+of+Stockholders/26784328.html Fri, 17 Jul 2026 16:05:00 -0400 A.23795053 O.20329759 O.30693091 VXRT http://www.streetinsider.com/Globe+Newswire/Vaxart+Announces+Results+of+Annual+Meeting+of+Stockholders/26784328.html <p align="justify">SOUTH SAN FRANCISCO, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, yesterday held its Annual Meeting of Stockholders (the “Annual Meeting”) in a virtual-only format. Results from the Annual Meeting indicate that two proposals were approved and one proposal was rejected by Vaxart stockholders.</p> <p align="justify">Stockholders voted in favor of the following proposals in alignment with the Board of Directors’ recommendations:</p> <ul type="disc"><li style="text-align:justify;">Election of six director nominees to serve http://www.streetinsider.com/Globe+Newswire/Vaxart+Announces+Results+of+Annual+Meeting+of+Stockholders/26784328.html Fri, 17 Jul 2026 16:05:00 -0400 A.23795053 O.20329759 O.30693091 VXRT http://www.streetinsider.com/Globe+Newswire/Vaxart+Announces+Results+of+Annual+Meeting+of+Stockholders/26784328.html <p align="justify">SOUTH SAN FRANCISCO, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, yesterday held its Annual Meeting of Stockholders (the “Annual Meeting”) in a virtual-only format. Results from the Annual Meeting indicate that two proposals were approved and one proposal was rejected by Vaxart stockholders.</p> <p align="justify">Stockholders voted in favor of the following proposals in alignment with the Board of Directors’ recommendations:</p> <ul type="disc"><li style="text-align:justify;">Election of six director nominees to serve http://www.streetinsider.com/Globe+Newswire/Vaxart+Announces+Results+of+Annual+Meeting+of+Stockholders/26784328.html Fri, 17 Jul 2026 16:05:00 -0400 A.23795053 O.20329759 O.30693091 VXRT http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+06/26738884.html si-local-file:///var/storage/secattach/20260707/26738884.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+06/26738884.html Tue, 07 Jul 2026 08:01:00 -0400 O.20329759 VXRT